I'm long a small position in SNSS @$2.00 . 2 years ago I took a fairly sizable position in ACAD @$1.75. The story of a "failed" PIII trial had driven ACAD to that PPS , but DD showed "the rest of the story". Fast-forward to today ... ACAD @$26.50 with price targets from $35 - $45 and NDA to be submitted (with breakthrough therapy designation) by year end. I am not predicting that SNSS will be $26 in 2 years , but there are a lot of similarities between the 2 companies (and their stock). SNSS's "failed" trial had some silver linings ... kinda like ACAD 2 years ago.
disclosure : I have added to ACAD all the way up and currently own a substantial # of shares long.
Hundreds of million dollar spent on trials and salaries and the result is: nothing.
Never earned $1 shareholdervalue in it's history.
I had a bid in this morning for 2K at 1.42 and it would not hit